MDxHealth today announced that it has been awarded a US Government Services Administration (GSA) supply contract to use ConfirmMDx for Prostate Cancer within the Department of Veterans Affairs (VA).
The five-year contract, effective February 1, 2017, provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA Health System.
According to the VA, prostate cancer is the most frequently diagnosed cancer among veterans with roughly 12,000 new cases annually. Over 600 urologists serve the 152 VA hospitals across the US and it is estimated that more than 200,000 prostate biopsies are performed within the VA healthcare system each year.
“MDxHealth is proud to support the Department of Veterans Affairs with ConfirmMDx testing to help improve patient management and decision-making on the need for prostate biopsies,” stated Dr. Jan Groen, CEO of MDxHealth. “This contract further underscores ConfirmMDx’s clinical value for prostate cancer risk assessment and will be a significant new driver of test volume.”
More on MDx Health here.
